Marwan Ghabril Herbert L Bonkovsky Clarissa Kum Tim Davern Paul H Hayashi David E Kleiner Jose Serrano Jim Rochon Robert J Fontana Maurizio Bonacini US Drug-Induced Liver Injury Network
10.1016/j.cgh.2012.12.025
Clin Gastroenterol Hepatol
2013 May;11(5):558-564.e3.
author_manuscript
https://pubmed.ncbi.nlm.nih.gov/23333219/
Antibodies, Monoclonal / adverse effects Antibodies, Monoclonal, Humanized / adverse effects Chemical and Drug Induced Liver Injury Immunoglobulin G / adverse effects Immunologic Factors / adverse effects Tumor Necrosis Factor-alpha / antagonists & inhibitors
Antibodies, Monoclonal / adverse effects Antibodies, Monoclonal, Humanized / adverse effects Chemical and Drug Induced Liver Injury Immunoglobulin G / adverse effects Immunologic Factors / adverse effects Tumor Necrosis Factor-alpha / antagonists & inhibitors Case Reports Research Support, N.I.H., Extramural Review Adalimumab Adult Antibodies, Monoclonal / administration & dosage Antibodies, Monoclonal, Humanized / administration & dosage Autoimmune Diseases / chemically induced Cholestasis / chemically induced Etanercept Female Humans Immunoglobulin G / administration & dosage Immunologic Factors / administration & dosage Infliximab Liver / pathology Male Receptors, Tumor Necrosis Factor / administration & dosage Severity of Illness Index United States Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Immunoglobulin G Immunologic Factors Receptors, Tumor Necrosis Factor TNF protein, human Tumor Necrosis Factor-alpha Infliximab Adalimumab Etanercept
PMC3865702
23333219
Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases
2013